Compare ALUR & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALUR | CVKD |
|---|---|---|
| Founded | 2009 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 18.4M |
| IPO Year | N/A | 2023 |
| Metric | ALUR | CVKD |
|---|---|---|
| Price | $1.68 | $10.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.25 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 506.0K | 27.5K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,208,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $8.12 |
| 52 Week High | $16.81 | $22.90 |
| Indicator | ALUR | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 54.37 | 44.66 |
| Support Level | $1.37 | $8.12 |
| Resistance Level | $1.79 | $11.58 |
| Average True Range (ATR) | 0.18 | 0.87 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 88.31 | 50.24 |
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.